CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Convalescent SARS COVID-19 plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria

A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of clinical status at day 30 after study initiation.

NCT04383535 SARS Virus SARS-CoV-2 COVID-19 Other: Convalescent SARS COVID-19 plasma Other: Placebo
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Ordinal outcome with six mutually exclusive categories to describe the patient's clinical status during follow-up. The six categories are: (1) death; (2) in intensive care; (3) hospitalised but requiring supplemental oxygen; (4) hospitalised and not requiring supplemental oxygen; (5) discharged but unable to resume normal activities; or (6) discharged with full resumption of normal activities.

Measure: Clinical status during follow-up at 30th day

Time: 30th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma)

Secondary Outcomes

Description: Ordinal outcome with six mutually exclusive categories to describe the patient's clinical status during follow-up. The six categories are: (1) death; (2) in intensive care; (3) hospitalised but requiring supplemental oxygen; (4) hospitalised and not requiring supplemental oxygen; (5) discharged but unable to resume normal activities; or (6) discharged with full resumption of normal activities.

Measure: Clinical status during follow-up at 7th day

Time: 7th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma)

Description: Ordinal outcome with six mutually exclusive categories to describe the patient's clinical status during follow-up. The six categories are: (1) death; (2) in intensive care; (3) hospitalised but requiring supplemental oxygen; (4) hospitalised and not requiring supplemental oxygen; (5) discharged but unable to resume normal activities; or (6) discharged with full resumption of normal activities.

Measure: Clinical status during follow-up at 14th day

Time: 14th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma)

Description: Hospital discharge or intrahospital death

Measure: Time until hospital discharge (days).

Time: Whenever the patient is discharge from the hospital or die without discharge, through study completion, an average of 14 days from admission

Description: ICU discharge or ICU death

Measure: Time until discharge from ICU (days)

Time: Whenever the patient is discharge from ICU or die in ICU, through study completion, an average of 10 days from admission

Description: Death and time to death

Measure: Time to death

Time: In a 30 days follow up period

Description: Time until complete functional recovery (according to basal status).

Measure: Time until complete functional recovery

Time: Whenever the patient returns to basal functional status until 1 month from discharge

Description: Percentage of participants with adverse events / serious adverse events

Measure: Percentage of participants with adverse events / serious adverse events

Time: In a 30 days follow up period

Description: Percentage of patients with negative SARS-CoV-3 PCR

Measure: Percentage of patients with negative SARS-CoV-3 PCR at Day 14th

Time: 14th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma)

Description: D Dimer plasma concentration

Measure: D Dimer plasma concentration at Day 14th

Time: 14th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma)

Description: Ferritin plasma concentration

Measure: Ferritin plasma concentration at Day 13th

Time: 13th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma)

Description: Plasma concentration of neutralizing antibodies

Measure: Plasma concentration of neutralizing antibodies at Day 2nd

Time: 2nd Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma)

Description: Plasma concentration of neutralizing antibodies

Measure: Plasma concentration of neutralizing antibodies at Day 7th

Time: 7th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma)

Description: Post-transfusion adverse reactions between study groups

Measure: Post-transfusion adverse reactions

Time: In a 30 days follow up period


Related HPO nodes (Using clinical trials)